Violation of endothelial function in patients with renal transplant


DOI: https://dx.doi.org/10.18565/therapy.2019.2.36-41

Rogozina L.A., Lymareva L.V., Osadchuk A.M., Zolotovskaya A.I., Davydkin I.L.

Samara State medical University of the Ministry of Healthcare of Russia
Aim of the study is to determine the role of endothelial dysfunction in the functional state of allogenic renal transplant in the late postoperative period. Material and methods. A total of 79 patients who underwent primary cadaveric allotransplantation of the kidney were divided into two groups depending on the glomerular filtration rate (GFR). In the first group, the GFR was <60 ml / min; there were 52 patients; in the second group with GFR ≥ 60 ml / min, there were 27 people. The concentration of plasminogen activator inhibitor - I (PAI-1), endothelin-I (ET-1), C-reactive protein in serum (CRP) was assessed. The calculation of GFR was made according to the formula CKD-EPI using a renal calculator. Results. In the group of patients with GFR<60 ml / min, a statistically significant increase in the level of ET-1, CRP, PAI-I was detected compared with individuals with GFR ≥ 60 ml / min. Conclusion. It was shown that in patients in the late postoperative period after allogeneic renal transplantation with GFR values less than 60 ml / min, higher values of endothelial dysfunction markers are determined.
Keywords: plasminogen-activator inhibitor, endothelin-I, renal graft dysfunction, endothelial dysfunction, C-reactive protein
Read entire article

Literature


  1. Hill N.R., Fatoba S.T., Oke J.L., Hirst J.A., O’Callaghan C.A., Daniel S. Lasserson, Hobbs R.F.D. Global prevalence of Chronic Kidney Disease – a systematic review and meta-analysis. PLoS One. 2016; 11(7): e0158765. doi: 10.1371/journal.pone.0158765.

  2. O’Callaghan C.A., Shine B., Lasserson D.S. Chronic kidney disease: a large-scale population-based study of the effects of introducing the CKD-EPI formula for eGFR reporting. BMJ. open. 2011; 1(2): e000308 doi: 10.1136/bmjopen-2011-000308.

  3. Douglas C.A. Palliative care for patients with advanced chronic kidney disease. J. R. Coll. Physicians Edinb. 2014; 44: 224–31.

  4. Samaan F., Requião-Moura L.R., Pinheiro H.S., Ozaki K.S., Saraiva Câmara N.O., Pacheco-Silva A. Prevalence and progression of chronic kidney disease after renal transplantation. Transplant Proc. 2011; 43(7): 2587–91. doi: 10.1016/j.transproceed. 2011.05.055.

  5. Wang J.H., Skeans M.A., Israni A.K. Current Status of Kidney Transplant Outcomes: Dying to Survive Adv. Chronic Kidney Dis. 2016; 23(5): 281–86.

  6. Manna G.L., Capelli I., Gasperoni L., Comai G., Ravaioli M., Marchetti A., Rucci P., D’Arcangelo G.L., Faenza S., Pinna A.D., Scolar M.P. Long Term Outcomes of Kidney Transplant: Characteristics of Recipients with 20 or More Years of Graft Survival. J. Med. Surg. Pathol. 2016; 1: 2. doi: 10.4172/2472-4971.1000109.

  7. Cardinal H., Dieudé M., Hébert M.-J. Endothelial Dysfunction in Kidney Transplantation. Front. Immunol. 2018; 9: 1130.

  8. Małgorzewicz S., Skrzypczak-Jankun E., Jankun J. Plasminogen activator inhibitor-1 in kidney pathology (Review). Int. J. Mol. Med. 2013; 31: 503–10.

  9. Zahran M., Nasr F.M., Metwaly A.A., El-Sheikh N., Khalil N.S.A., Harba T. The Role of Hemostatic Factors in Atherosclerosis in Patients with Chronic Renal Disease. Electr. Phys. 2015; 7(5): 1270–76.

  10. Abushufa A.M., Eldehni M.T., Odudu A., Evans P. D., O'Sullivan S.E., McIntyre C.W. Defining Uremic Arterial Functional Abnormalities in Patients Recently Started on Haemodialysis: Combined In Vivo and Ex Vivo Assessment. PLoS One. 2014; 9(12): e113462.

  11. Рогозина Л.А., Давыдкин И.Л., Парабина Е.В. Маркеры эндотелиальной дисфункции у пациентов с аллогенным почечным трансплантатом в поздний послеоперационный период. Нефрология и диализ, 2018; 3: 112–115.


About the Autors

Larisa A. Rogozina, PhD, associate professor of the hospital therapy with courses of out-patient therapy and transfusiology «Samara State medical University» of the Ministry of Healthcare of Russia. Address: 443079, Samara, 165B Karl Marx Avenue. Tel.: +7 (927) 657-41-62. E-mail: larisarogozina@tambler.ru
Larisa V. Limareva, MD, leading researcher at the Institute of experimental medicine and biotechnology «Samara State medical University» of the Ministry of Healthcare of Russia, the chief visiting hematologist of the Ministry of Healthcare of the Samara region. Tel.: +7 (905) 017-89-92. Address: 443079, Samara, 20 Gagarina St. Tel.: +7 (905) 017-89-92. E-mail: larisa.limareva@yandex.ru
Aleksey M. Osadchuk, MD., professor, of the hospital therapy with courses of out-patient therapy and transfusiology «Samara State medical University» of the Ministry of Healthcare of Russia. Address: 443079, Samara, 165B Karl Marx Avenue. Tel.:+7 (927) 606-09-40. E-mail: maxlife2004@mail.ru
Irina A. Zolotovskaya, PhD, associate professor of the hospital therapy with courses of out-patient therapy and transfusiology Department of FSBEI of Higher Education «Samara State medical University» of the Ministry of Healthcare of Russia. Address: 443079, Samara, 165B Karl Marx Avenue. Tel.: +7 (927) 768-78-94. E-mail: zolotovskay@list.ru
Igor L. Davydkin, MD, Professor, pro-rector for scientific and innovative work, head of the Department of hospital therapy with polyclinic therapy and transfusiology, director of the Research institute of hematology, transfusiology and intensive care FSBEI of Higher Education «Samara State medical University» of the Ministry of Healthcare of Russia, the chief visiting hematologist of the Ministry of Healthcare of the Samara region. Address: 443079, Samara, 165B Karl Marx Avenue. Tel.: +7 (927) 014-55-44. E-mail: dagi2006@rambler.ru


Similar Articles

Back to Content

Бионика Медиа